Safety of Endostar in combination with chemotherapy in patients with cancer
The occurrence of AEs during Endostar and chemotherapy treatment differed across different tumor types and chemotherapy regimens. No new unexpected Endostar-related AEs were observed. The total dose of Endostar was not associated with an increased risk of severe (Grade ≥3) thrombocytopenia and abnormal white blood cell counts when used in combination with chemotherapy in the real-life setting.
Authors
- Dai‐Hong Guo (ORCID: https://orcid.org/0000-0002-0536-9478)
- Lei Xia (ORCID: https://orcid.org/0000-0003-0394-945X)
- Dongxiao Wang (ORCID: https://orcid.org/0000-0001-5358-196X)
- Changhong Zhao
- Man Zhu (ORCID: https://orcid.org/0000-0003-0627-2800)
- Jin Gu (ORCID: https://orcid.org/0000-0001-6277-9062)
- Tianlin Wang (ORCID: https://orcid.org/0000-0001-6950-0183)
- Xiaowu Huang
Institutions
- Chinese PLA General Hospital (CN)
- Peking University Shougang Hospital (CN)
Publication Details
- Journal
- Indian Journal of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/ijc.ijc_1065_20
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00